RCKT
Income statement / Annual
Last year (2023), Rocket Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Rocket Pharmaceuticals, Inc.'s net income was -$245.60 M.
See Rocket Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$7.10 M |
$6.27 M |
$5.37 M |
$1.15 M |
$426,000.00 |
$330,000.00 |
$204,000.00 |
$169,000.00 |
$45,000.00 |
$0.00 |
| Gross Profit |
-$7.10 M |
-$6.27 M |
-$5.37 M |
-$1.15 M |
-$426,000.00 |
-$330,000.00 |
-$204,000.00 |
-$169,000.00 |
-$45,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$186.34 M
|
$165.57 M
|
$125.48 M
|
$106.38 M
|
$58.62 M
|
$53.27 M
|
$14.19 M
|
$31.99 M
|
$12.55 M
|
$5.59 M
|
| General & Administrative
Expenses |
$73.32 M
|
$58.77 M
|
$41.77 M
|
$27.92 M
|
$17.53 M
|
$17.89 M
|
$12.54 M
|
$9.89 M
|
$7.84 M
|
$2.11 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$73.32 M
|
$58.77 M
|
$41.77 M
|
$27.92 M
|
$17.53 M
|
$17.89 M
|
$12.54 M
|
$9.89 M
|
$7.84 M
|
$2.11 M
|
| Other Expenses |
$0.00 |
-$500,000.00 |
-$1.00 M |
$0.00 |
-$250,000.00 |
$186,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$259.66 M |
$223.84 M |
$166.25 M |
$134.30 M |
$75.90 M |
$70.97 M |
$26.74 M |
$41.88 M |
$20.40 M |
$7.70 M |
| Cost And Expenses |
$259.66 M |
$223.84 M |
$166.25 M |
$134.30 M |
$75.90 M |
$70.97 M |
$26.74 M |
$41.88 M |
$20.40 M |
$7.70 M |
| Interest Income |
$15.94 M |
$3.89 M |
$3.07 M |
$2.15 M |
$3.41 M |
$1.69 M |
$819,000.00 |
$443,000.00 |
$89,000.00 |
$0.00 |
| Interest Expense |
$1.88 M |
$1.91 M |
$5.89 M |
$7.55 M |
$4.78 M |
$5.24 M |
$3.58 M |
$1.42 M |
$1.23 M |
$980,000.00 |
| Depreciation &
Amortization |
$7.10 M
|
$6.27 M
|
$5.37 M
|
$1.15 M
|
$426,000.00
|
$330,000.00
|
$204,000.00
|
$169,000.00
|
$45,000.00
|
$0.00
|
| EBITDA |
-$236.62 M
|
-$213.69 M
|
-$161.72 M
|
-$131.59 M
|
-$71.14 M
|
-$71.16 M
|
-$26.74 M
|
-$41.27 M
|
-$20.26 M
|
-$7.70 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$14.06 M
|
$2.48 M
|
-$1.82 M
|
-$5.40 M
|
-$1.12 M
|
-$3.36 M
|
-$2.76 M
|
-$975,000.00
|
-$47.59 M
|
-$1.83 M
|
| Income Before Tax |
-$245.60 M |
-$221.86 M |
-$169.07 M |
-$139.70 M |
-$77.27 M |
-$74.52 M |
-$29.50 M |
-$42.85 M |
-$67.98 M |
-$9.53 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$2.48 M |
$516,000.00 |
$6.97 M |
$5.96 M |
$2.68 M |
$819,000.00 |
$443,000.00 |
$1.23 M |
$0.00 |
| Net Income |
-$245.60 M |
-$219.38 M |
-$169.59 M |
-$146.67 M |
-$83.23 M |
-$74.52 M |
-$29.50 M |
-$42.85 M |
-$67.98 M |
-$9.53 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.92 |
-3.22 |
-2.68 |
-2.65 |
-1.7 |
-1.89 |
-4.36 |
-6.41 |
-14.85 |
-2.79 |
| EPS Diluted |
-2.92 |
-3.22 |
-2.68 |
-2.65 |
-1.7 |
-1.89 |
-4.36 |
-6.41 |
-14.85 |
-2.79 |
| Weighted Average Shares
Out |
$84.01 M
|
$68.15 M
|
$63.24 M
|
$55.38 M
|
$49.01 M
|
$39.38 M
|
$6.77 M
|
$6.68 M
|
$4.58 M
|
$3.42 M
|
| Weighted Average Shares
Out Diluted |
$84.01 M
|
$68.15 M
|
$63.24 M
|
$55.38 M
|
$49.01 M
|
$39.38 M
|
$6.77 M
|
$6.68 M
|
$4.58 M
|
$3.42 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
